Background New drugs and new evidence concerning the use of established treatments have
become available since the publication of the first European League Against Rheumatism …

… Florence Tubach… f 27 not considered for this analysis due to a diagnosis other than ARI. …
f Two trials focusing on outpatients were excluded from this analysis (Long 2009; Long 2011). …

Background The clinical utility of serum procalcitonin levels in guiding antibiotic treatment
decisions in patients with sepsis remains unclear. This patient-level meta-analysis based on …

Background Reduced duration of antibiotic treatment might contain the emergence of
multidrug-resistant bacteria in intensive care units. We aimed to establish the effectiveness of an …

Background The timing of renal-replacement therapy in critically ill patients who have acute
kidney injury but no potentially life-threatening complication directly related to renal failure is …

Background: In clinical trials, at the group level, results are usually reported as mean and
standard deviation of the change in score, which is not meaningful for most readers. Objective: …

… monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The
three‐year prospective french research axed on tolerance of biotherapies registry - Tubach - …

Background In February, 2017, the US Food and Drug Administration approved the blood
infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory …

… F Tubach1, … Dr F Tubach … Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy
N, et al. Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip …

… F Tubach2, … ; Prieur Anne Marie; Ravaud Philippe; Roux Christian; Salmon Dominique;
Tubach Florence; Vittecoq Daniel.The validation-cases expert committee comprised three …